Home/Pipeline/LPH-48

LPH-48

CNS disorders

Pre-clinicalActive

Key Facts

Indication

CNS disorders

Phase

Pre-clinical

Status

Active

Company

Lophora

About Lophora

Lophora is a Danish private biotech company pioneering next-generation psychedelic-inspired therapeutics for central nervous system disorders. Its core technology is a rational drug design platform focused on creating selective 5-HT2A receptor agonists with optimized drug-like properties. The company's lead asset, LPH-5, has successfully completed Phase I trials, positioning it as a potential rapid-acting, non-hallucinogenic treatment for major depressive disorder and other conditions. Lophora is backed by notable Danish public funders and experienced biotech investors.

View full company profile

Therapeutic Areas

Depression Anxiety PTSD Eating Disorders Substance Use Disorders Mood Disorders Neurodegenerative Disease

Other CNS disorders Drugs

Drug	Company	Phase	Status
NanoBUP™	Nanopharmaceutics	Clinical	Active
PRX-3140	Nanopharmaceutics	Clinical	Active
NP-18-2	Nanopharmaceutics	Clinical	Active
NP-18-3	Nanopharmaceutics	Clinical	Active
Research Collaboration with OliX Pharmaceuticals	Vect-Horus	Research	Active
ANAVEX®1-41	Anavex Life Sciences	Preclinical	Preclinical
New Discovery Programs	CAMP4 Therapeutics	Discovery	Active discovery
Next-Gen α7 NAM Program	Neuphoria Therapeutics	Discovery/Preclinical	Active